How large is the cerebral adrenoleukodystrophy (cald) market, and what is its growth trajectory?
The cerebral adrenoleukodystrophy (CALD) market size has grown rapidly in recent years. It will grow from $6.58 billion in 2024 to $7.56 billion in 2025 at a compound annual growth rate (CAGR) of 14.9%. The growth in the historic period can be attributed to rising awareness of rare diseases, increased newborn screening programs, growing focus on neurodegenerative disorders, introduction of lorenzo’s oil, research on peroxisomal disorders, advocacy by patient support groups and improved healthcare infrastructure.
The cerebral adrenoleukodystrophy (CALD) market size is expected to see rapid growth in the next few years. It will grow to $13.05 billion in 2029 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period can be attributed to emergence of gene therapy solutions, expansion of newborn screening technologies, development of targeted drug delivery systems, growing investment in rare disease research, increased adoption of digital health tools, rising demand for personalized treatments, collaborations between biotech and pharma companies and enhanced awareness through global advocacy campaigns. Major trends in the forecast period include gene editing using clustered regularly interspaced short palindromic repeats (CRISPR), Al-powered diagnostic algorithms, advanced neuroimaging techniques, next-generation sequencing advancements, brain-targeted nanomedicine, wearable devices for neurological monitoring, digital twin simulations for treatment planning, cloud-based genomic data sharing, virtual reality for caregiver training and blockchain for secure patient data management.
Get Your Free Sample of The Global Cerebral Adrenoleukodystrophy (CALD) Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21135&type=smp
What are the key forces behind the cerebral adrenoleukodystrophy (cald) market’s growth in recent years?
The incremental healthcare spending is expected to propel the growth of the cerebral adrenoleukodystrophy (CALD) market going forward. Healthcare spending is increasing due to aging populations, chronic diseases, medical advancements, rising drug costs, and expanded health coverage. Healthcare spending supports cerebral adrenoleukodystrophy (CALD) by enabling advancements in diagnostic tools, funding innovative treatments such as gene therapy and stem cell transplantation, and improving patient access to specialized care and early intervention. For instance, in December 2024, according to the Centers for Medicare And Medicaid Services (CMS), a US-based federal agency, national health expenditures (NHE) grew by 7.5% in 2023, outpacing the gross domestic product (GDP) growth of 6.1%. Between 2023 and 2032, average national health expenditures (NHE) are projected to grow at an average annual rate of 5.6%, increasing the health spending share of domestic product (GDP) from 17.3% in 2022 to 19.7% in 2032. Therefore, incremental healthcare spending is driving the growth of the cerebral adrenoleukodystrophy (CALD) market.
What are the major segments of the cerebral adrenoleukodystrophy (cald) market?
The cerebral adrenoleukodystrophy (CALD) market covered in this report is segmented –
1) By Type Of Treatment: Dietary Management, Medications, Stem Cell Therapy
2) By Patient Age Group: Adults, Children, Infants, Teens
3) By End User: Healthcare Facilities, Patients And Caregivers, Pharmaceutical Companies
Subsegments:
1) By Dietary Management: Lorenzo’s Oil, Omega-3 Fatty Acids, Fatty Acid Supplements
2) By Medications: Corticosteroids, Antioxidants, Anti-inflammatory Drugs
3) By Stem Cell Therapy: Hematopoietic Stem Cell Transplantation (HSCT), Gene Therapy
Order your report now for swift delivery
Which companies dominate the cerebral adrenoleukodystrophy (cald) market?
Major companies operating in the cerebral adrenoleukodystrophy (CALD) market are Pfizer Inc., Sanofi S.A., Novartis AG, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, Poxel S.A., Neuraxpharm Group, Viking Therapeutics Inc., MedDay Pharmaceuticals SAS, Calico Life Sciences, Magenta Therapeutics Inc., SOM Biotech, Minoryx Therapeutics S.L., NeuroVia Inc., SwanBio Therapeutics Inc., Autobahn Therapeutics Inc., Bluebird Bio Inc., Orpheris Inc., Sperogenix Therapeutics, Abliva
What major trends will shape the cerebral adrenoleukodystrophy (cald) market during the forecast period?
Major companies operating in the cerebral adrenoleukodystrophy (CALD) market are focusing on developing innovative therapies, such as gene therapies, to provide more effective and long-term solutions for halting disease progression, improving patient outcomes, and potentially offering curative treatments for this rare and life-threatening disorder. Gene therapy is a medical treatment that involves altering or replacing faulty genes within a patient’s cells to treat or cure diseases. For instance, in September 2022, Bluebird Bio Inc., a US-based biotechnology company, received accelerated approval for Skysona (elivaldogene autotemcel) from the United States Food and Drug Administration (FDA) to slow the progression of neurologic dysfunction in boys aged 4-17 with early, active cerebral adrenoleukodystrophy (CALD). Skysona is a one-time gene therapy that uses ex-vivo transduction with the Lenti-D lentiviral vector (LVV) to add functional copies of the ABCD1 gene into a patient’s hematopoietic stem cells (HSCs). This new gene allows patients to produce the ALD protein (ALDP), which can then participate in the local degradation of very long-chain fatty acids (VLCFAs), which is believed to slow or possibly prevent further inflammation and demyelination.
What are the key regional dynamics of the cerebral adrenoleukodystrophy (cald) market, and which region leads in market share?
North America was the largest region in the cerebral adrenoleukodystrophy (CALD) market in 2024. The regions covered in the cerebral adrenoleukodystrophy (CALD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Cerebral Adrenoleukodystrophy (CALD) Market Report 2025 Offer?
The cerebral adrenoleukodystrophy (cald) market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Cerebral adrenoleukodystrophy (CALD) is a rare, progressive neurological disorder that primarily affects males and is caused by mutations in the ABCD1 gene. It is characterized by the accumulation of very long-chain fatty acids in the brain, which destroys myelin, the protective covering of nerve cells. Cerebral adrenoleukodystrophy (CALD) is a form of adrenoleukodystrophy (ALD) that involves the brain and spinal cord, causing symptoms such as cognitive decline, behavioral changes, and motor dysfunction.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21135
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
